In vitro activity of cefepime and other broad-spectrum β-lactams tested against 129 mec A-negative Staphylococcus spp. Isolates: A multicenter sample

Diagnostic Microbiology and Infectious Disease

Volumn 30, Issue 1, 1998, Pages 65-69

  Marshall, Steven A ^a   Wilke, Werner W ^a   Chen, Yao Shen ^a   Pfaller, Michael A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

BACTERICIDAL ACTIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 0031940959     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00175-2     Document Type: Article

References (17)

1. Aldridge KE. Cefotaxime in the treatment of staphylococcal infections. Comparison of in vitro and in vivo studies. Diagn Microbiol Infect Dis. 22:1995;195-201.
2. Barradell LB, Bryson HM. Cefepime a review of its antibacterial activity, pharmacokinetic properties and therapeutic use . Drugs. 47:1994;471-505.
3. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in Gram-positive bacteria, enterococci, staphylococci, and non pneumococcal streptococci. Drugs. 51:(suppl 1):1996;6-12.
4. Cormican MG, Wilke WW, Barrett MS, Pfaller MA, Jones RN. Phenotypic detection of mec A-positive staphylococcal blood stream isolates high accuracy of simple disk diffusion tests . Diagn Microbiol Infect Dis. 25:1996;107-112.
5. Dholakia N, Rolston KU, Ho DH, LeBlanc B, Streeter H, Dvorak T, Bodey GP. In vitro activity of FK-037, a novel parenteral cephalosporin, against bacterial isolates from neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 13:1994;679-684.
6. Frei R, Jones RN, Pignatari AC, Yamane N, Marco R, Hoban DJ. Antimicrobial activity of FK-037 a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime . Diagn Microbiol Infect Dis. 18:1994;167-173.
7. Jones RN, Fuchs PC. Activity of cefepime (BMY-28142) and cefpirome (HR 810) against Gram-negative bacilli resistant to cefotaxime or ceftazidime. J Antimicrob Chemother. 23:1989;163-165.
8. Jones RN, Kehrberg EN, Erwin ME. Prevalence of important pathogens and antimicrobial activity of parenteral pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistance real or perceived? Diagn Microbiol Infect Dis. 19:1994;203-215.
9. Lamb LB, Hibbard JR, Desiderio JM, Yuan HT. Efficacy of cefepime in a Staphylococcus aureus endocarditis rat model. J Antimicrob Chemother. 32:(suppl B):1993;95-101.
10. Marshall SA, Wilke WW, Pfaller MA, Jones RN (1998) Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mec A) characterization in the SCOPE Program. Diagn Microbiol Infect Dis (in press).
11. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (4th ed). Approved Standard M7-A4. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (5th ed). Suggested Standard M100-S8. 1998;National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Panililio A, Culver DH, Gaynes RP. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
14. Sanders CC, Moland ES. Cefepime the last generation or the first enhanced-potency broad spectrum cephalosporin . Clin Drug Invest. 10:1995;344-354.
15. Spangler SK, Jacob MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK-037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 38:1994;898-900.
16. Steckelberg JM, Rouse MS, Tallan BM, Osmon DR, Henry NK, Wilson WR. Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. Antimicrob Agents Chemother. 37:1993;554-558.
17. Thornsberry C, Yee YC. Comparative activity of eight antibiotics against clinical bacterial isolates from the United States broth microdilution (MicroScan) and the Etest methods . Am J Med. 100:(suppl 6A):1996;26S-38S.